文献速递类风湿关节炎其他结缔组织病

免疫检查点抑制剂治疗后发生类风湿关节炎与风湿性多肌痛

Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment.
PubMed 文献 · Ann Rheum Dis · 2017-06-09

该回顾性研究报告10例接受免疫检查点抑制剂(ICI)治疗后出现关节炎或关节痛并诊断为类风湿关节炎(RA)或风湿性多肌痛(PMR)的患者。RA或PMR在中位1个月(范围1至9个月)后发生,所有患者均无既往风湿或自身免疫病史,除一例外免疫治疗均持续至癌症进展。这是首例报道ICI治疗后发生RA的研究,PMR也可在ICI治疗后发生。

要点

  • ICI治疗后中位1个月可发生RA或PMR,患者均无既往风湿病史
  • 6例RA患者抗CCP抗体均阳性,3例检测者中2例在免疫治疗前已检出抗CCP抗体
  • 所有病例对糖皮质激素或免疫抑制治疗有应答,多数免疫治疗得以继续

核心结论

  • 这是首例报道免疫检查点抑制剂治疗后发生RA的研究,PMR也可在ICI治疗后发生。
  • 所有RA和PMR病例对糖皮质激素或免疫抑制治疗有应答。

研究设计与样本

  • 回顾性研究,纳入接受ICI治疗后出现关节炎或关节痛并诊断为RA或PMR的患者10例。

主要发现

  • 10例患者均接受抗PD-1或抗PD-L1抗体治疗,RA或PMR在中位1个月(范围1至9个月)后发生。
  • 无患者有既往风湿或自身免疫疾病。
  • 6例发生RA,均抗CCP抗体阳性,4例类风湿因子阳性;3例检测者中2例在免疫治疗前检出抗CCP抗体。
  • 4例诊断为PMR,均对糖皮质激素有应答。
  • 3例RA患者需使用改善病情抗风湿药,另3例接受糖皮质激素或非甾体抗炎药。

临床怎么用

  • 风湿科与肿瘤科协作对识别和管理ICI相关RA和PMR至关重要。
  • ICI治疗后出现关节炎或关节痛需考虑RA或PMR,并检测抗CCP抗体和类风湿因子。

局限性

  • 回顾性研究,样本量小(10例),部分检测数据不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 and programmed cell death protein 1 (PD-1) have demonstrated improved survival for multiple cancers. However, these new drug classes have led to increased immune-related adverse events (IrAE). Rheumatic IrAEs have not been well described in clinical trials. We report here cases of rheumatoid arthritis (RA) and polymyalgia rheumatica (PMR) occurring after ICI treatment. METHODS: This was a retrospective study of patients receiving an ICI in whom symptoms of arthritis or arthralgia developed and revealed a diagnosis of RA or PMR. RESULTS: In 10 patients who received ICI therapy (all anti-PD-1 or anti-PDL1 antibodies), RA or PMR developed at a median of 1 month (1 to 9) after exposure. No patient had pre-existing rheumatic or autoimmune disease. RA developed in six patients; all six were positive for anti-cyclic citrullinated peptide (anti-CCP) antibodies and four for rheumatoid factor. Anti-CCP antibodies were detected in two out of three patients tested before immunotherapy. Disease-modifying antirheumatic drugs were needed for three patients; the three others received corticosteroids or non-steroid anti-inflammatory drugs. PMR was diagnosed in four patients, all responded to corticosteroids. Despite these IrAEs, immunotherapy was pursued for all but one patient until cancer progression. CONCLUSIONS: This is the first description of RA occurring after ICI therapy for cancer. PMR can also occur after ICI, particularly after anti-PD-1 therapy. All cases responded to corticosteroids or with immunosuppressive therapy. Collaboration between rheumatologists and oncologists is crucial and could lead to better recognition and care of these patients.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Belkhir R, Burel SL, Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017. PMID: 28600350. doi:10.1136/annrheumdis-2017-211216

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。